The assays use nucleic acid extracted from specimens that previously tested positive. Credit: Fernando Zhiminaicela / Pixabay.

PerkinElmer has introduced two research-use-only (RUO) assays for the detection of genomic mutations linked to SARS-CoV-2 variants.

The PKamp VariantDetect SARS-CoV-2 RT-PCR Assay and next-generation sequencing-based NEXTFLEX Variant-Seq SARS-CoV-2 Kit use nucleic acid extracted from specimens that previously tested positive.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

After identifying a positive case with the help of a first-tier diagnostic assay, second-tier assays such as the PerkinElmer PKamp VariantDetect and NEXTFLEX Variant-Seq kits could offer further information about mutations in the specimen.

In addition, the PKamp VariantDetect SARS-CoV-2 RT-PCR Assay can identify mutations linked to the predominant variant strains, B.1.1.7, B.1.351, and P.1 variants.

The workflow of NEXTFLEX Variant-Seq SARS-CoV-2 WGS can identify all SARS-CoV-2 genetic changes linked to the strain, which was originally detected in Wuhan, China.

PerkinElmer diagnostics senior vice-president Masoud Toloue said: “While continuing to rely on gold-standard RT-PCR tests for Covid-19 diagnosis, we must understand emerging variants to effectively limit the spread of the virus.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The second-tier assays made available today are the outcome of a product development engine primed to continue producing assays that will help labs outpace the virus.”

In a separate development, the company has concluded the acquisition of UK-based company Oxford Immunotec.

The move comes after PerkinElmer reached an agreement to acquire Oxford Immunotec for approximately $591m in January.

Oxford Immunotec focuses on test kits for latent tuberculosis. Its Interferon Gamma Release Assay (IGRA) offering can detect people infected with tuberculosis.

PerkinElmer president and CEO Prahlad Singh said: “Oxford Immunotec’s global role in fighting tuberculosis, particularly its trademark product, the T-SPOT.TB test, and the operations it has built are remarkable.

“We recognise the distinct clinical and logistical advantages of the test and see a great opportunity to leverage our automation capabilities and commercial channel access to bring tuberculosis testing to more customers around the world.”